Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Richard Greil; D Rischin; KJ Harrington; D Soulieres; M Tahara; G de Castro; A Psyrri; N Baste; P Neupane; A Bratland; T Fuereder; BGM Hughes; R Mesia; N Ngamphaiboon; T Rordorf; WZW Ishak; J Lin; RF Swaby; B Gumuscu; B Burtness

doi:10.1016/j.annonc.2020.08.1030

Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Richard Greil, D Rischin, KJ Harrington, D Soulieres, M Tahara, G de Castro, A Psyrri, N Baste, P Neupane, A Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZW Ishak, J Lin, RF Swaby, B Gumuscu, B Burtness

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

8 Citations (Web of Science)

Original language	English
Pages (from-to)	S660-S661
Journal	ANNALS OF ONCOLOGY
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.08.1030
Publication status	Published - 2020
Event	ESMO Virtual Congress - ELECTR NETWORK Duration: 19 Sept 2020 → 18 Oct 2020

Access to Document

10.1016/j.annonc.2020.08.1030

Cite this

Greil, R., Rischin, D., Harrington, KJ., Soulieres, D., Tahara, M., de Castro, G., Psyrri, A., Baste, N., Neupane, P., Bratland, A., Fuereder, T., Hughes, BGM., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, WZW., Lin, J., Swaby, RF., Gumuscu, B., & Burtness, B. (2020). Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). ANNALS OF ONCOLOGY , 31, S660-S661. https://doi.org/10.1016/j.annonc.2020.08.1030

Greil, Richard ; Rischin, D ; Harrington, KJ et al. / Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). In: ANNALS OF ONCOLOGY 2020 ; Vol. 31. pp. S660-S661.

@article{36cb69bef0d240ac90c8361603ff94d5,

title = "Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)",

author = "Richard Greil and D Rischin and KJ Harrington and D Soulieres and M Tahara and {de Castro}, G and A Psyrri and N Baste and P Neupane and A Bratland and T Fuereder and BGM Hughes and R Mesia and N Ngamphaiboon and T Rordorf and WZW Ishak and J Lin and RF Swaby and B Gumuscu and B Burtness",

year = "2020",

doi = "10.1016/j.annonc.2020.08.1030",

language = "English",

volume = "31",

pages = "S660--S661",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "ESMO Virtual Congress ; Conference date: 19-09-2020 Through 18-10-2020",

}

Greil, R, Rischin, D, Harrington, KJ, Soulieres, D, Tahara, M, de Castro, G, Psyrri, A, Baste, N, Neupane, P, Bratland, A, Fuereder, T, Hughes, BGM, Mesia, R, Ngamphaiboon, N, Rordorf, T, Ishak, WZW, Lin, J, Swaby, RF, Gumuscu, B & Burtness, B 2020, 'Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)', ANNALS OF ONCOLOGY , vol. 31, pp. S660-S661. https://doi.org/10.1016/j.annonc.2020.08.1030

Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). / Greil, Richard; Rischin, D; Harrington, KJ et al.
In: ANNALS OF ONCOLOGY , Vol. 31, 2020, p. S660-S661.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

AU - Greil, Richard

AU - Rischin, D

AU - Harrington, KJ

AU - Soulieres, D

AU - Tahara, M

AU - de Castro, G

AU - Psyrri, A

AU - Baste, N

AU - Neupane, P

AU - Bratland, A

AU - Fuereder, T

AU - Hughes, BGM

AU - Mesia, R

AU - Ngamphaiboon, N

AU - Rordorf, T

AU - Ishak, WZW

AU - Lin, J

AU - Swaby, RF

AU - Gumuscu, B

AU - Burtness, B

PY - 2020

Y1 - 2020

U2 - 10.1016/j.annonc.2020.08.1030

DO - 10.1016/j.annonc.2020.08.1030

M3 - Abstract (Journal)

SN - 0923-7534

VL - 31

SP - S660-S661

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - ESMO Virtual Congress

Y2 - 19 September 2020 through 18 October 2020

ER -

Greil R, Rischin D, Harrington KJ, Soulieres D, Tahara M, de Castro G et al. Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). ANNALS OF ONCOLOGY . 2020;31:S660-S661. doi: 10.1016/j.annonc.2020.08.1030